Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Alumis Inc. Common StockNASDAQ: ALMS
Short-term Investments · Q2 FY2026 · quarter ended Jun 2026
Short-term investments rises 31.1% from a year ago
Short-term investments stood at $438.59M at the end of Q2 FY2026, up 31.1% from a year earlier and down 4.5% from the prior quarter. Over 3 fiscal years it compounded at +48.2% a year.
Context
- Short-term investments amounted to 78.2% of total assets at the end of Q2 FY2026, up 23.5 pp from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +31.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 218.83M USD
- Year-over-year change
- +84.3%
- 3-year CAGR
- +48.2%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 218.83M | +84.3% |
| FY2024 | 2024-12-31 | 118.74M | +3916.8% |
| FY2023 | 2023-12-31 | 2.96M | -95.6% |
| FY2022 | 2022-12-31 | 67.26M | — |
Short-term Investments vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +31.1% is the 3rd highest of 7, against a peer median of -24.5%.
- Short-term investments amounts to 78.2% of total assets for ALMS, versus a peer median of 24.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | Jun 2026 | $438.59M USD | +31.1% | +48.2% | 78.2% |
| Mar 2026 | $122.27M USD | +289.8% | +50.2% | 24.2% | |
| Mar 2026 | $76.76M USD | +2.4% | -25.7% | 38.6% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $65.83M USD | -51.4% | — | 62.1% |
| Mar 2026 | $57.01M USD | — | — | 57.1% | |
| Mar 2026 | $37.99M USD | -84.3% | -41.7% | 11.5% | |
| Mar 2026 | €24.83M EUR | +33.7% | -22.6% | 50.7% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €0 EUR | — | — | 0.0% |
| Dec 2025 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -24.5% | -24.1% | 24.2% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.